Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales

Sino Biopharmaceutical

19/08/2026 09:42

Overview
China pharma group's H1 2026 revenue rose 10.6% yr/yr, driven by innovative drug sales
Net profit attributable to owners grew 1.4% yr/yr, supported by revenue growth
Company declared interim dividend and highlighted new licensing deals with Sanofi, AstraZeneca, GSK

Outlook
Company expects nearly 30 national category 1 innovative drugs to be approved from 2026 to 2030
Sino Biopharmaceutical says out-licensing collaborations to become a major revenue stream
Result Drivers
INNOVATIVE DRUGS - Co said double-digit revenue growth was driven by increased sales of innovative drugs and out-licensing, which rose 44.3% yr/yr and accounted for 45.2% of total revenue
NEW PRODUCT APPROVALS - Co said performance benefited from approvals of new national category 1 and 2 innovative drugs and expanded indications
LICENSING DEALS - Co said new international licensing collaborations with Sanofi, AstraZeneca and GSK provided additional revenue streams and supported growth

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.94 bln
 
H1 Net Income Attributable
 
RMB 3.43 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Sino Biopharmaceutical Limited is HK$8.50, about 77.3% above its August 18 closing price of HK$4.80
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 17 - China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
Aug 17 - AstraZeneca suffers another setback as it halts volrustomig lung cancer trial
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-19/4c300728-27cb-4af4-9caf-55540639b0f9.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)